\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Horizon EuropeThere is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The Commission has published the dates of the INFO DAYS they have planned for each Horizon Europe domain: https://www.horizon-europe-infodays2021.eu/
Additionally herewith attached you can find an overview of this information together with the links to the latest drafts of the Work programmes, and if available additional information about opening and closing of the calls. We will update regularly this overview which you will be able to consult through linking to this news item.
We will continue to post and email the latest detailed information about the infodays and the work programmes per Horizon Europe domain separately. You can always check your profile through the "go to my horizon" button on the homepage
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
